Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a positive outlook with strong financial performance, including record revenue and growth in EBITDA. The Q&A section reveals minimal impact from tariffs and optimism about infrastructure projects. Despite refurbishment delays, the company's financial health is solid, with a stable debt ratio and increased EPS. The reaffirmation of guidance and shareholder return plans, along with organic growth expectations, further supports a positive sentiment. Considering the market cap, the stock price is likely to experience a moderate positive movement in the short term.
Revenue Record Q3 top line revenue of $237.3 million, grew by 13% year-over-year. The growth was driven by solid demand in end markets, both local customer and project-based work, and investments in sales and marketing initiatives.
Adjusted EBITDA Adjusted EBITDA grew by 15% year-over-year, with a margin increase of 40 basis points to 28.2%. This reflects strong operational efficiencies and optimization of overhead support functions.
Revenue Per Truck Per Month (RPT) RPT was $47,921 in Q3, up 8% compared to last year. This improvement reflects better fleet utilization and pricing efforts.
Hydrovac Production 57 hydrovacs were manufactured in Q3, compared to 48 units in Q3 of last year, reflecting increased demand from end markets.
Fleet Growth The fleet grew by 5% since Q3 of last year, ending the quarter with 1,703 hydrovacs. Revenue and profitability grew at more than double the rate of fleet growth, showcasing operating leverage and capital efficiencies.
G&A Expenses G&A expenses were $10.6 million or 4% of revenue, compared to $9.8 million or 5% of revenue last year, indicating improved scalability and cost management.
Adjusted Earnings Per Share (EPS) Adjusted EPS was $0.91 per share, up 25% compared to last year, driven by revenue and adjusted EBITDA growth.
Debt to EBITDA Ratio Compliance leverage ended the quarter at 1.3x debt to EBITDA, down from 1.5x in the same quarter last year, reflecting a stable and strong balance sheet.
Hydrovac production: Produced 57 hydrovacs in Q3 2025, up from 48 units in Q3 2024. Full-year production expected at the upper end of 180-210 units due to increased demand.
Fleet growth: Fleet grew by 5% year-over-year, ending the quarter with 1,703 hydrovacs.
Denver market consolidation: Consolidated a Badger franchise in Denver, gaining full control of the market and accelerating fleet refresh to increase market share.
Strategic market branches: Targeted growth in strategic market branches to meet increasing demand in key U.S. regions and metropolitan areas.
Revenue growth: Achieved record Q3 revenue of $237.3 million, a 13% increase year-over-year.
Adjusted EBITDA: Increased by 15% year-over-year, with margins rising by 40 basis points to 28.2%.
Revenue per truck per month (RPT): Improved to $47,921 in Q3, up 8% year-over-year.
Refurbishment program: Reduced 2025 refurbishment target from 50-60 units to 30-40 units due to third-party capacity issues. Plans to develop an in-house refurbishment facility by 2026.
Infrastructure projects: Focused on large infrastructure projects such as airports, light rail, petrochemical facilities, LNG facilities, and data centers.
Energy sector demand: Increased demand for power generation and transmission, including nuclear, natural gas, and solar projects.
Severe Winter Weather: The company highlighted the need for preparedness for severe winter weather, which could disrupt operations and pose safety risks to employees and equipment.
Refurbishment Program Delays: The refurbishment program has lagged expectations due to third-party facility capacity issues, leading to a reduction in the refurbishment target for 2025. This could impact fleet efficiency and operational costs.
Increased Capital Expenditure: The company expects to increase its 2025 capital spending range, which could strain financial resources and impact profitability if not managed effectively.
Dependence on Third-Party Facilities: Delays in the refurbishment program were attributed to third-party facility capacity, highlighting a dependency that could pose risks to operational timelines and costs.
Market Recovery Uncertainty: While the company noted market recovery, there is an implied risk of potential fluctuations in demand, particularly in key U.S. regions and metropolitan areas.
Hydrovac Production: Badger expects 2025 hydrovac production to be at the upper end of the original 180 to 210 unit range due to increased demand from end markets.
Fleet Retirements: 2025 retirements are expected to be at the upper end of the original 90 to 130 unit range, driven by the accelerated refresh of the Denver market fleet.
Refurbishment Program: The 2025 refurbishment range has been reduced from the original 50 to 60 units to 30 to 40 units due to third-party facility capacity constraints. A new refurbishment facility in the Central U.S. is planned to be operational in 2026.
Capital Expenditures: The 2025 capital spend range has been increased from the original $95 million to $115 million range to now between $115 million to $130 million, reflecting increased hydrovac production, Denver franchise consolidation, and targeted growth in strategic market branches.
Market Outlook: Badger anticipates sustained growth in key U.S. regions and large metropolitan areas through the remainder of 2025 and into 2026, supported by robust demand in infrastructure projects, power generation, and aged infrastructure renewal.
Dividend Program: The company has maintained its ability to return capital to shareholders through dividends. However, no specific details about dividend amounts or changes were provided in the transcript.
Share Buyback Program: The company renewed its NCIB (Normal Course Issuer Bid) program in the third quarter, allowing for opportunistic share purchases. However, no shares were purchased under this program during the third quarter.
The earnings call presents a positive outlook with strong financial performance, including record revenue and growth in EBITDA. The Q&A section reveals minimal impact from tariffs and optimism about infrastructure projects. Despite refurbishment delays, the company's financial health is solid, with a stable debt ratio and increased EPS. The reaffirmation of guidance and shareholder return plans, along with organic growth expectations, further supports a positive sentiment. Considering the market cap, the stock price is likely to experience a moderate positive movement in the short term.
The company's financial performance shows strong operating cash flow and free cash flow, with significant year-over-year growth. Despite some guidance reaffirmations indicating declines, organic growth in key segments like plasma and hospital business is strong. The Q&A highlights positive sentiment about sustainable growth in Blood Management Technologies and plasma collections, alongside strategic initiatives like share repurchases and the Vivasure acquisition. While some uncertainties remain, overall financial health and strategic direction are positive, suggesting a stock price increase in the coming weeks.
The earnings call highlights strong organic growth, optimistic guidance, and strategic initiatives to address market challenges. Despite temporary softness in certain segments, the company is taking proactive measures, such as hiring new leaders and reorganizing teams, which instill confidence. Strong gross margins and a positive outlook for plasma and hospital segments further support a positive sentiment. However, the lack of clear guidance on plasma collections and competitive pressures in vascular closure warrant cautious optimism. Considering the market cap, a positive stock price movement of 2% to 8% is anticipated.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.